dc.contributor.author | Alcalde-Cabero, Enrique | |
dc.contributor.author | Almazan-Isla, Javier | |
dc.contributor.author | Garcia Lopez, Fernando Jose | |
dc.contributor.author | Ara-Callizo, José Ramón | |
dc.contributor.author | Avellanal, Fuencisla | |
dc.contributor.author | Casasnovas, Carlos | |
dc.contributor.author | Cemillán, Carlos | |
dc.contributor.author | Cuadrado, José Ignacio | |
dc.contributor.author | Duarte, Jacinto | |
dc.contributor.author | Fernández-Pérez, María Dolores | |
dc.contributor.author | Fernández, Óscar | |
dc.contributor.author | Merino, Juan Antonio García | |
dc.contributor.author | Montero, Rosa García | |
dc.contributor.author | Montero, Dolores | |
dc.contributor.author | Pardo, Julio | |
dc.contributor.author | Rodríguez-Rivera, Francisco Javier | |
dc.contributor.author | Ruiz-Tovar, Maria | |
dc.contributor.author | Pedro-Cuesta, Jesus de | |
dc.date.accessioned | 2017-09-04T16:28:42Z | |
dc.date.available | 2017-09-04T16:28:42Z | |
dc.date.issued | 2016-05-21 | |
dc.identifier.citation | BMC Neurol. 2016; 16:75 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/4814 | |
dc.description.abstract | BACKGROUND: Studies have shown a slight excess risk in Guillain-Barré syndrome (GBS) incidence associated with A(H1N1)pdm09 vaccination campaign and seasonal trivalent influenza vaccine immunisations in 2009-2010. We aimed to assess the incidence of GBS as a potential adverse effect of A(H1N1)pdm09 vaccination. METHODS: A neurologist-led network, active at the neurology departments of ten general hospitals serving an adult population of 4.68 million, conducted GBS surveillance in Spain in 2009-2011. The network, established in 1996, carried out a retrospective and a prospective study to estimate monthly alarm thresholds in GBS incidence and tested them in 1998-1999 in a pilot study. Such incidence thresholds additionally to observation of GBS cases with immunisation antecedent in the 42 days prior to clinical onset were taken as alarm signals for 2009-2011, since November 2009 onwards. For purpose of surveillance, in 2009 we updated both the available centres and the populations served by the network. We also did a retrospective countrywide review of hospital-discharged patients having ICD-9-CM code 357.0 (acute infective polyneuritis) as their principal diagnosis from January 2009 to December 2011. RESULTS: Among 141 confirmed of 148 notified cases of GBS or Miller-Fisher syndrome, Brighton 1-2 criteria in 96 %, not a single patient was identified with clinical onset during the 42-day time interval following A(H1N1)pdm09 vaccination. In contrast, seven cases were seen during a similar period after seasonal campaigns. Monthly incidence figures did not, however, exceed the upper 95 % CI limit of expected incidence. A retrospective countrywide review of the registry of hospital-discharged patients having ICD-9-CM code 357.0 (acute infective polyneuritis) as their principal diagnosis did not suggest higher admission rates in critical months across the period December 2009-February 2010. CONCLUSIONS: Despite limited power and underlying reporting bias in 2010-2011, an increase in GBS incidence over background GBS, associated with A(H1N1)pdm09 monovalent or trivalent influenza immunisations, appears unlikely | |
dc.language.iso | eng | |
dc.publisher | BioMed Central (BMC) | |
dc.type.hasVersion | VoR | |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | Guillain-Barré syndrome | |
dc.subject | Influenza A virus H1N1 subtype | |
dc.subject | Influenza vaccines | |
dc.subject | Public health surveillance | |
dc.subject | Safety | |
dc.subject | ICD-9-CM | |
dc.title | Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database | |
dc.type | journal article | |
dc.rights.license | Atribución 3.0 España | * |
dc.format.volume | 16 | |
dc.format.number | 1 | |
dc.format.page | 75 | |
dc.identifier.doi | 10.1186/s12883-016-0598-z | |
dc.description.peerreviewed | Sí | |
dc.identifier.e-issn | 1471-2377 | |
dc.relation.publisherversion | https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-016-0598-z | |
dc.identifier.journal | BMC Neurology | |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | |
dc.repisalud.institucion | ISCIII | |
dc.rights.accessRights | open access | es_ES |